Margin Surge Masks a Growth Miss — Anthem's ₹211 Crore Quarter Requires Scrutiny
Reported profit grew 21.9% YoY on margin expansion, but revenue rose just 8% — a sharp miss versus the prior implied ≥20% guidance. The call reveals a company pivoting on cost, not scale.
₹594 Cr
+8% YoY vs prior ≥20%
₹211 Cr
+21.9% YoY
50.6%
+300 bps QoQ
~48%
ex ₹59 Cr other income
The tension is stark. Anthem's profit jumped 22%, but the revenue that feeds it grew just 8% — half what prior guidance implied. The delta comes from two places: a 300-basis-point margin expansion driven by China de-risking and in-house manufacturing ramp, and ₹59 crore in other income (likely MTM or fair-value gains) that inflates the bottom line. Strip that out, and underlying EBITDA margin is ~48%, still strong but not the 50.6% headline. The real story: Anthem swapped growth for margin — a defensive posture that signals caution on the biotech order book.
Management's claims vs. what holds up
Robust Q2 performance with strong growth
OverstatedRevenue ₹594 Cr, +8% YoY (Q1 weak, Q2 recovery +42% QoQ). PAT ₹211 Cr, +21.9% YoY.
Margin expansion sustained, operating leverage intact
SupportedEBITDA 50.6%, PAT 32.04% in Q2. QoQ improvement from reduced China reliance (now ~20–21% of procurement) confirmed.
Double-digit growth will be delivered for FY27
OverstatedH1 YoY growth implied ~7–8% (₹1,012 Cr vs prior-year ~943 Cr). Q1 weak, Q2–Q4 catch-up needed. Management now hedges: 'try to deliver double-digit.'
Capex ₹1,200 Cr for Unit 4 Phase 1 remains on track
SupportedFY27 capex ₹700 Cr intact, Unit 4 Phase 1 ₹1,200 Cr over 2 years reaffirmed. Phase 2 equivalent scale post-approval (FY28).
What changed on this call
Growth guidance vagueness: Prior call implied FY27 growth 'intact' and 'in line with historical performance' (≥20% threshold). Q2 delivery of +8% YoY signals a miss. Management now defers to 'try to deliver double-digit growth' — stripped of specificity, this is a retreat. Gawir Baig (CFO) explicitly refused to quantify: 'We refrain from giving any guidance on what the full year number is.'
Margin expansion confirmed via China de-risking: China procurement fell from historic highs to ~20–21% of procurement. In-house manufacturing ramp and product mix (higher-margin molecules) drove the 300-bps EBITDA margin improvement. This is durable cost discipline, not a one-off. But it masks lumpy order flow: Q1 was weak, Q2 recovery required, Q2–Q4 catch-up pending.
Capex roadmap reaffirmed, but new tech unquantified: FY27 capex ₹700 Cr and Unit 4 Phase 1 (₹1,200 Cr, commissioning starts Mar 2028) remain intact. New tech (peptides, ADCs, oligonucleotides) still early — in development since 2014 with no FY31 revenue contribution quantified. Ajay Bhardwaj (MD/CEO): 'FY31, we have not even done this calculation.'
Pipeline milestone: One molecule moved from late-stage to commercial in Q2 (chronic-care indication). Five recent commercializations carry ~$10 billion aggregate market potential. But 9 late-stage molecules remain on an 18–24 month timeline with trial outcomes outside Anthem's control.
The honest read
Anthem is executing on cost and capex, but growth has stalled. The margin expansion masks a company managing order lumpiness — Q1 weak, Q2 recovery, Q2–Q4 catch-up required. The prior call's implicit ≥20% FY27 growth target now reads as over-optimistic; management's current 'try to deliver double-digit' is a hedge that signals execution uncertainty. What changed: cost discipline is real, but growth guidance credibility is worn.
For holders, the debate hinges on whether biotech funding stabilizes and late-stage molecules commercialize on the expected 18–24 month timeline. For fresh money, the risk/reward tilts toward caution: the stock has rallied 57.7% off its 52-week low but now sits 6.5% below its all-time high, suggesting limited upside cushion if FY27 growth disappoints again.
Revenue growth shortfall vs. guidance
HighQ2 +8% YoY vs. prior ≥20% implied. H1 ~7–8% makes FY27 double-digit target challenging. If Q3–Q4 growth disappoints, stock faces downside risk.
Customer concentration (top 5 = 50%, top 10 = 80%)
HighSingle customer loss or wallet-share reduction could materially impact revenue. Biotech customer base also exposed to M&A cycles and funding volatility.
Late-stage pipeline timing uncertainty (9 molecules, 18–24 months)
HighCommercialization outcomes depend on trial results (not Anthem's control). Delay or failure impacts near-term and mid-term growth trajectory.
Biotech funding volatility and geopolitical headwinds
MediumRFP/RFQ inflow improved but AI crowding and geopolitical uncertainty dampen order book visibility. Order lumpiness (Q1 weak, Q2 recovery) signals customer hesitation.
Earnings quality / other income dependency
Medium₹59 Cr other income (vs ₹48 Cr prior year) inflates headline profit. Underlying EBITDA margin ~48%, not 50.6%. If other income normalizes, profit growth resets lower.
New tech commercialization unquantified (FY31 target missing)
MediumUnit 4 capex (₹1,200 Cr) betting on peptides, ADCs, oligonucleotides still in early stages (since 2014). No revenue target for FY31 — capex ROI visibility absent. Typical 6–7 years to Phase 3.
How the street is positioned
Price action and valuation context: Anthem trades at ₹913.55, above its SMA20 (₹843.26), SMA50 (₹881.51), and SMA200 (₹771.35). RSI 66.6 signals neutral momentum (not overbought). The stock sits 6.5% below its all-time high of ₹977.45 and 57.7% above its 52-week low of ₹579.15 — a strong recovery from the trough, but diminishing upside to ATH. Volume remains normal; no panic or euphoria on the tape.
Institutional flows — accumulation signal: FII holdings rose from 1.28% (Q4 FY26) to 2.58% (Q1 FY27), a +1.3pp increase. DII holdings rose from 11.55% to 13.48%, a +1.93pp increase. Promoter holdings fell from 74.68% to 71.42%, a -3.26pp step. The net: institutions are adding, promoters are trimming slightly (likely to fund capex or optimize holding). This is a mild bullish signal — FII/DII accumulation often precedes a sustained move — but the scale is modest, not aggressive.
Bulk/block deals (last 6 months): All major blocks were buys, at ₹744.80 — a price 22.6% below the current ₹913.55. UTI MF, SBI MF, WhiteOak Capital MF, and others accumulated on weakness. No promoter or insider sales near the highs — a clean record. The bulk buying by MFs on dips suggests confidence in the long-term story, but occurred when the stock was materially cheaper. No insider signal of near-term strength.
The tension: The market has repriced Anthem 57.7% higher from the 52-week low, betting on capex and margin expansion. But it has not yet repriced for the revenue growth miss. If Q3–Q4 fail to accelerate growth toward double-digit, the stock faces a test: institutional holders (who just added) will face a credibility gap between the capex roadmap and the delivery, and the 6.5% headroom to ATH may vanish.
1 · Q3 FY27 earnings: growth inflection or disappointment
Does management deliver mid-double-digit growth in Q3, or does the order lumpiness persist? H1 growth ~7–8% means Q3–Q4 average needs to hit ~15%+ to reach FY27 double-digit. This is the crux test for bulls.
2 · Late-stage pipeline updates: commercialization rate
How many of the 9 late-stage molecules move toward commercial status? Management expects 'at least a few' in FY27–FY28. Concrete progress validates the capex thesis; silence signals pipeline risk.
3 · Unit 4 commissioning timeline and Phase 1 ramp
Commissioning starts Mar 2028. Capacity ramp a multi-quarter process. Will new capacity fill with biotech/big pharma order flow, or sit idle amid funding volatility? This determines whether capex (₹1,200 Cr over 2 years) generates ROI.
4 · Customer concentration relief: do new tech/big pharma partnerships dilute top-5 risk?
Management claims 8–9 big pharma direct relationships emerging. Block/lateral contract wins with secondary suppliers would ease the top-5 = 50% concentration. Announcements on new wins matter.
5 · Specialty Ingredients (SI) 20% target: execution or promise?
SI flat in Q2 due to weak CRDMO. Management wants SI at ≥20% of sales (currently 15%). If SI stalls while CDMO growth disappoints, this target remains unmet.
Anthem delivered steady execution on cost and capex, but not on growth. The 8% revenue growth is a step backward from prior guidance, and management's pivot to a vague 'try to deliver double-digit' for FY27 signals execution uncertainty. The margin expansion is durable and credible — a win. But it masks an order book that remains lumpy and a biotech customer base still managing funding volatility. The capex roadmap (Unit 4 ₹1,200 Cr, commissioning Mar 2028) is the multi-year bull case; the near-term debate is whether revenue can recover to double-digit without new capacity coming online.
The number to track from here: FY27 full-year revenue growth. If Q3–Q4 deliver sub-double-digit growth, the guidance miss becomes permanent, and the stock's 57.7% rally from the 52-week low faces headwind. Institutional holders just added on dips; they will expect management to deliver on the implicit ≥20% thesis. A third consecutive miss accelerates de-rating risk.
Strong margins mask modest growth; pipeline depth justifies capex
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Capex guidance ₹700 Cr and Unit 4 ₹1,200 Cr reaffirmed. Growth guidance ('double-digit try to deliver') not quantified; Q2 8% YoY does not track prior 'in line with historical' (~20%) implied threshold.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Strong margin expansion (+300 bps QoQ via China de-risking) and robust capex roadmap (Unit 4 ₹1,200 Cr) back the long-term story. But Q2 revenue growth of 8% YoY misses the prior implied ≥20% guidance, and management's vague 'double-digit' FY27 aspiration signals execution uncertainty. Customer concentration (top 5 = 50%) and pipeline timing risk (18–24 months on 9 molecules) cap near-term upside.
₹594 Cr
Revenue · +8% YoY₹211.5 Cr
Reported PAT · +21.9% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
Robust Q2 performance with strong growth
OVERSTATEDRevenue ₹594 Cr, +8% YoY (modest), +42% QoQ (strong). PAT ₹211 Cr, +21.9% YoY
Margin expansion sustained, operating leverage intact
METEBITDA 50.6%, PAT 32.04% in Q2. QoQ improvement from reduced China reliance confirmed
Double-digit growth will be delivered for FY27
OVERSTATEDH1 YoY growth implied ~7-8% (₹1,012 Cr vs prior-year ~943 Cr). Q1 weak, Q2-Q4 catch-up needed
Capex ₹1,200 Cr for Unit 4 Phase 1 remains on track
METConfirmed intact in call. Phase 2 equivalent to Phase 1 after approval. Total ₹700 Cr capex FY27 reaffirmed
Strong pipeline: 15 commercial, 9 late-stage molecules
METOne molecule moved to commercial in Q2. Market potential $10B from newly commercialized assets. 18-24 month uncertainty on late-stage timing
Earnings quality
What changed since the last call
Margin expansion confirmed +300 bps QoQ
UpgradeEBITDA 50.6% in Q2 (vs 48% implied in prior Q1 soft quarter). Driven by reduced China reliance (down to ~20% of procurement) and manufacturing internalization.
Revenue growth trajectory remains cautious
DowngradePrior call implied FY27 growth 'intact' & 'in line with historical' (≥20%). Q2 delivery +8% YoY. Management now says 'double-digit try to deliver'—vague, not quantified.
Capex guidance (₹700 Cr, Unit 4 ₹1,200 Cr) reaffirmed
NeutralNo change vs prior call. Unit 4 Phase 2 scale TBD pending board approval post-Phase 1 commissioning (Mar 2028).
Specialty Ingredients: target 20%+ of sales
NewCurrently 15% (₹85 Cr in Q2). Mgmt wants 20%+ allocation; margins profitable, business flat due to weak CRDMO sales.
Biotech funding environment: improving but mixed
UpgradeIncreased RFP/RFQ inflow noted; geopolitical uncertainty and AI investment crowding concerns mentioned. Net: cautiously optimistic.
The Q&A
Analysts pressed on growth guidance specificity (Anish), new tech FY31 contribution (Sidharth), late-stage timeline certainty (Bansi), and customer concentration (Sidharth). Mgmt deflected growth numbers (Gawir: 'refrain from giving guidance'), hedged new tech (Ajay: 'hard to predict'), acknowledged 18–24 month late-stage timing uncertainty. Overall: analysts skeptical, management held firm but offered no new numeric anchors.
Customer expectations & moat — Akash, Individual Investor
AnsweredCustomers now see Anthem as solution provider, not just contract manufacturer. Track record of IP generation and multiple options solving the problem differentiates us. Complexity-focused strategy works.
Commercial pipeline progression — Gourav Bhama, JM Financial
AnsweredYes, one moved to commercial in Q2. Good indication of chronic-care category. Prospects good due to indication on chronic-care category.
Revenue geography & concentration — Sidharth Negandhi, CWC
Answered84% international (86% of CDMO). U.S. 22–24%, Europe 60%, ROW 1–2%. Top 5 ≈50%, top 10 ≈80%. China reliance down to ~20–21% of procurement from prior high; moving onshore.
Currency impact on growth — Vijay Shah, Prudential Global
AnsweredMinimal. INR/USD range-bound (94.5–96.5) this quarter. Currency not material contributor. Growth organic.
Capex guidance integrity — Vijay Shah, Prudential Global
AnsweredIntact. ₹1,200 Cr capex for Unit 4 Phase 1 over next two years, largely committed. Phase 2 equivalent to Phase 1, post-approval.
Gross margin improvement drivers — Roni Naik, Arete Group
AnsweredMix of both: reduced China sourcing (now ~20–21%), in-house manufacturing ramp, and product mix with higher-margin molecules. Multiple customers drive different margin profiles.
Margin sustainability — Anish, ICICI Life
PartialUptick due to operating leverage and cost efficiencies. We delivered ~50% EBITDA margin this quarter, well above last year's 43%. Sustainable but already at high levels. Cannot promise 50% forever, but confident in EBITDA and PAT growth.
FY27 full-year growth target — Anish, ICICI Life
DodgedWe refrain from giving full-year guidance. Historically we deliver double-digit growth, and we will try to deliver that. Q1 was low, Q2–Q4 catch-up ongoing.
Newly commercialized molecules: revenue ramp — Bansi Desai, JP Morgan
AnsweredFive recent commercializations with ~$10 Bn aggregate market potential. Acquired by big pharma at significant sums. Will make meaningful contributions in next 3–4 years.
Late-stage pipeline commercialization rate — Bansi Desai, JP Morgan
PartialHard to predict. 18–24 months is our expectation window. A few could commercialize in FY27; most need to wait. Dependent on trial outcomes, which we don't control.
Specialty Ingredients: growth outlook — Isha, Invest Yaadnya
AnsweredTarget SI at 20%+ of sales minimum. Currently flat this quarter due to weak CRDMO. Margins high and profitable. Expect both SI and CDMO to grow simultaneously.
GTM U.S. & biotech reliance — Sidharth Negandhi, CWC
AnsweredGTM via Davos (50-year partner): transparent, experienced access without capex burden. Biotech has been forte; now 8–9 big pharma direct relationships. M&A trends: biotech gets acquired when in Phase III or approved. Over 100 projects with biotech expected to yield high acquisition rate.
New tech contribution to FY31 revenue — Sidharth Negandhi, CWC
DodgedHard to quantify. Working on since 2014, still early. Cannot predict what % of FY31. Investing for future, guided by customer demand.
Patent expiry headroom — Saion Mukherjee, Nomura
AnsweredFirst patent expiry 2032, not immediate. Older molecules still growing. Lots of headroom. Patent expiry 2032, 2037, 2040, so significant runway.
New molecule revenue potential — Saion Mukherjee, Nomura
AnsweredNew molecules peak sales vary: $1–4 Bn each, $10 Bn aggregate. Old molecules also significant. Different indications drive different profiles. On average, new and old molecules similar revenue potential.
Lateral contracts as alternate revenue — Saion Mukherjee, Nomura
AnsweredStrong traction. Being qualified for other products. No tech transfer yet, so sole supplier now. Once acquired, second suppliers will follow. Ramp-up slow but being discussed; big win when it happens.
Big pharma positioning & capabilities — Amey Chalke, JM Financial
AnsweredWorking with 8–9 big pharma directly now. Emerging biotech was forte; now transitioning to big pharma partnerships. Need larger investments in biologic manufacturing and drug product (new areas). Unit 4 will house oligonucleotides and peptides.
Unit 4 capex allocation biology vs chemistry — Roni Naik, Arete Group
Answered30–35% biology, rest chemistry for Unit 4. Driven by customer demand and pipeline. Investment ongoing in cybersecurity and new modalities.
Guidance
FY27 double-digit growth targeted
MediumNo specific ₹ target given. Mgmt says 'try to deliver.' Historical precedent is 20%+; Q2 8% YoY signals miss vs prior 'in line with historical' guidance.
Specialty Ingredients: maintain 20%+ of sales
MediumCurrently 15%; target uplift. Dependent on SI growth while CDMO recovery.
EBITDA & PAT growth sustained; margins already high
High50.6% EBITDA, 32% PAT in Q2. Mgmt confident in sustainability; acknowledged already at high levels, cannot promise forever.
FY27 capex ₹700 Cr; Unit 4 Phase 1 ₹1,200 Cr (total)
HighReaffirmed intact. Phase 2 equivalent to Phase 1, post-approval. Commissioning starts Mar 2028.
Risks the call surfaced
Customer concentration
HighTop 5 customers account for ~50% of revenue; top 10 account for ~80%. Single customer loss could materially impact revenue.
Late-stage pipeline timing risk
HighNine late-stage molecules face 18–24 month commercialization uncertainty. Outcome depends on trial results (not Anthem's control). Delay or failure impacts growth trajectory.
Revenue growth shortfall
MediumQ2 revenue +8% YoY significantly below prior 'in line with historical (~20%)' and current 'double-digit' guidance. H1 growth ~7–8% makes FY27 double-digit target challenging.
Biotech funding volatility
MediumBiotech funding environment is mixed: increased RFPs/RFQs but geopolitical uncertainty and AI investment crowding concerns remain. Order book lumpiness tied to funding availability.
China supply chain reliance
MediumHistorically high reliance on China for raw materials. Though reduced to ~20–21% now, trade tensions or supply disruptions could still impact procurement cost/timeline.
New tech commercialization risk
MediumPeptides, ADCs, oligonucleotides, and other new modalities have been in development since 2014 but still early. Typical path 6–7 years to Phase 3. Revenue contribution to FY31 unquantified and highly uncertain.
Management
Score 8/10. Transparent on challenges (Q1 weakness, customer concentration, biotech funding volatility). Hedged on specifics (FY27 growth, new tech FY31 contribution) but explained reasoning (trial outcomes not controllable, new tech too early to predict). Capex ₹700 Cr FY27 and Unit 4 ₹1,200 Cr reaffirmed on track. Margin expansion (50.6% EBITDA) delivered via cost discipline and China de-risking. But Q2 revenue growth 8% YoY vs prior ≥20% implied guidance is a miss.
1 · Q3 FY27
Late-stage molecule commercialization updates; biotech funding feedback in RFP/RFQ pace
2 · Sep 2026–Mar 2027
At least a few of 9 late-stage projects expected to move toward commercial (18–24 month window)
3 · Mar 2028
Unit 4 Phase 1 commissioning begins; capacity ramp a multi-quarter process
Customer concentration (top 5 = 50%) and pipeline timing risk (18–24 months on 9 molecules) cap near-term upside.
Anthem Biosciences consolidated PAT +22% YoY, margins expand as revenue recovers from Q1
PAT +21.93% YoY · revenue +8% · margins expanding
₹594.03 Cr
+8% YoY
₹211.46 Cr
+21.93% YoY
32.39%
+3.4pp YoY
₹3.75
Anthem Biosciences posted consolidated revenue of ₹594.0 Cr (+8.0% YoY, +42.0% QoQ) and consolidated PAT of ₹211.5 Cr (+21.9% YoY, +76.3% QoQ) for Q2 FY27, with basic EPS of ₹3.75 against ₹3.09 a year ago. Neither this quarter nor the year-ago quarter carried exceptional items, so the YoY print is clean — no adjustment needed. Standalone PAT of ₹220.9 Cr runs about 4.3% ahead of the consolidated number, a divergence worth flagging since it reflects a drag from subsidiary Neoanthem Lifesciences rather than any inconsistency in the standalone figures.
Q2 FY-2027 vs prior quarters
The quarter's story is margin, not volume: operating margin expanded to 45.70% from 39.62% a year ago (+608 bps) and from 36.00% last quarter (+970 bps), while net margin rose to 35.60% from 28.99% YoY. The driver sits squarely on costs — total expenses actually fell 3.3% YoY to ₹356.6 Cr even as revenue grew 8%, with cost of materials consumed essentially flat (₹200.8 Cr, -0.2% YoY) and a favourable swing in inventory/work-in-progress. At the segment level, CRDMO — roughly 86% of revenue — grew 9.2% YoY to ₹509.3 Cr with segment profit up 28.1% YoY to ₹366.3 Cr, confirming the margin-led pattern; Speciality Ingredients was nearly flat, revenue +0.6% YoY to ₹84.8 Cr with profit +4.4% YoY.
The stock went into the print at ₹854.45, down 0.2% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records.
FY27 growth 'intact' and 'in line with historical performance' (implicitly ≥20%); no explicit number. FY27 capex ₹700 Cr. Unit 4 (₹1,200 Cr Phase 1) commissioned by end FY28 (+365 KL custom synthesis, +100 KL fermentation).
— This quarter: missed
No quarter-specific Street estimates for Anthem's Q2 FY27 turned up in search; full-year FY27 consensus revenue sits near ₹2,570 Cr, against which H1 FY27 actual revenue of ₹1,012.3 Cr implies a sizeable H2 step-up is still needed. On guidance: after Q1's shipment-timing-driven 22.6% YoY revenue decline, management told investors it expected deferred deliveries to recover across Q2-Q4 and reaffirmed confidence in returning to 'mid-teens'/historical FY27 growth. This quarter's +8% YoY growth and +42% QoQ rebound confirm the cautiously-optimistic near-term read from the Q1 concall, but still trail the guided mid-teens pace, and H1 cumulative revenue remains down 7.2% YoY at ₹1,012.3 Cr versus ₹1,091.4 Cr — so the guided recovery is only partially delivered through H1, putting the onus on H2. Separately, the company's September 8 settlement of its upside-sharing arrangement for ₹127.68 Cr does not surface as an exceptional item in either quarter's P&L, and other current/financial liabilities declined over the half — consistent with a provision being settled in cash rather than expensed now. No management press release was available for this filing to cross-check against their own framing.
W1
H2 FY27 delivery recovery: deferred Q1 shipments guided to convert across Q2-Q4 toward 'mid-teens' growth; H1 revenue still down 7.2% YoY at ₹1,012.3 Cr, so H2 needs a sharp step-up
W2
Margin durability: OPM hit a multi-quarter high of 45.70% this quarter vs 36-40% in the prior two quarters shown; watch whether the cost tailwind holds
W3
Unit 4 capex execution: ₹1,200 Cr Phase 1 (custom synthesis +365 KL, fermentation +100 KL) targeted for commissioning by end-FY28 against FY27 capex guidance of ₹700 Cr — track CWIP build-out pace
CRDMO Sustaining Growth | Street Unanimous on Runway
Anthem expects Q2 sequential growth from Q1's ₹4,182 Cr revenue, with CRDMO (86% of sales) leading. All 7 analysts rate Buy; target ₹885 implies 18% upside. Watch: guidance affirm and commercial molecule velocity.
The Setup
Anthem Biosciences enters Q2 FY27 with strong tailwinds from contract research and development (CRDMO) — a business that contributed 86% of H1 FY26 revenue and posted 8.5% year-on-year growth. Q1 FY27 laid a solid foundation at ₹4,182 Cr revenue with 39.6% EBITDA margin, though management flagged timing shifts in customer deliveries. Q2 is expected to show sequential growth as those delivery cycles normalize. The Street is firmly bullish: all 7 analysts covering Anthem rate Buy or Strong Buy, with a median target of ₹885 — implying 18% upside from the spot price of ₹829.9 (as of Oct 30).
What to Expect
~₹4,300–4,500 Cr
Sequential growth on Q1's ₹4,182 Cr; on-plan assuming normalized customer delivery timings
~39–41%
Consistent with recent run-rate; CRDMO service mix supports 40%+ structurally
~86%
Unchanged; commercial molecule revenue (56% of CRDMO) is the key driver to watch
TBD
Q1 was soft due to timing; Q2 expected to show momentum as customer projects ramp
A strong Q2 would show revenue accelerating toward ₹4,500 Cr or higher, EBITDA margin staying above 40%, and explicit guidance that commercial molecule growth is re-accelerating in H2. A weak Q2 would miss sequential growth (revenue stuck near ₹4,200 Cr), margin compression, or management commentary suggesting customer project delays persist into Q3.
On Track?
Anthem has not provided formal FY27 guidance in filings to date, so the on-plan benchmark is the quarterly trajectory. Q1 FY27 revenue of ₹4,182 Cr represents steady mid-to-high single-digit growth from Q4 FY26 levels, consistent with the company's pre-result commentary about "regaining mid-teens growth" as customer delivery timing normalizes. A Q2 print above ₹4,300 Cr would signal that normalization is happening and that the company remains on course for that medium-term growth target. Anything below ₹4,200 Cr would raise questions about whether the timing headwinds are proving more persistent.
What the Street Says
Since Last Quarter
Oct 28, 2026
Q2 FY27 results board meeting scheduled for Nov 3, 2026 — routine, on calendar
Board Meeting Intimation
Sep 24, 2026
Closed from Oct 1 until 48 hours after board approval — standard practice; no insider activity flagged
Trading Window Closure
Sep 8, 2026
₹1,276.83 Cr settlement (shareholder-approved at July AGM) — capital return, not operational impact
Upside Sharing Arrangement Settlement
Jul 21, 2026
Revenue ₹4,182 Cr, PAT ₹1,199 Cr, EBITDA ₹1,755 Cr (39.6%); revised results released same day
Q1 FY27 Results Release
Bulk/Block Deals Signal Institutional Confidence: Over the past ~6 months, multiple mutual funds and institutional buyers accumulated shares at ₹744.80 — including UTI MF (~5.3 Mn shares), SBI MF (~10.8 Mn shares), Mahindra Manulife MF, and Whiteoak Capital MF. No promoter or insider selling flagged; these are steady accumulation moves by long-only funds. Combined with the upside sharing settlement (a shareholder-friendly return of capital), the ownership picture remains constructive.
Three to Watch on Result Day
1 · Revenue & Sequential Momentum
Is Q2 revenue sequentially higher than Q1's ₹4,182 Cr? Management said Q1 was impacted by customer delivery timing. A rebound to ₹4,400+ Cr would confirm normalization; a stall or miss would raise concerns about demand persistence and delay guidance affirmation.
2 · Commercial Molecule Growth Story
Commercial molecules are 56% of CRDMO revenue and the key upside lever. Listen for: ramp-up timelines for major client molecules, any new molecule wins, and management confidence that commercial revenue growth is re-accelerating. Soft commentary here would justify a sell-off.
3 · FY27 Guidance & Margin Commentary
Management has not issued formal FY27 guidance. Does the board offer a growth range or margin outlook for the full year? Affirmation that mid-teens growth is achievable would align with Street consensus; a guide down would trigger a repricing.
Anthem Biosciences enters Q2 FY27 results with a clean setup: a high-margin CRDMO platform at scale, unanimous analyst backing, and institutional buyers accumulating. The bar is sequential revenue growth from Q1's ₹4,182 Cr, stable-to-improving EBITDA margin, and reassurance that commercial molecule ramps are on track. Delivery on these three fronts would vindicate the 18% upside that the Street is pricing in; any miss would test consensus and the stock's recent bounce from its lows.